Mindset Pharma’s CEO talks about new lead drug candidate MSP-1014, a potentially safer next generation psilocybin alternative used to assist people suffering from treatment-resistant depression.
Mindset Pharma’s CEO talks about new lead drug candidate MSP-1014, a potentially safer next generation psilocybin alternative used to assist people suffering from treatment-resistant depression.
In this episode of the Psychedelic Spotlight podcast we chat with James Lanthier, CEO of Mindset Pharma, a Toronto based drug discovery company focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC Markets under the symbol $MSSTF.
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
*To learn more about Mindset Pharma, visit their website: MindsetPharma.com
